This Study is to Assess the Efficacy and Safety of ZD6474 in Subjects With Non-small Cell Lung Cancer.
The purpose of this study is to assess the efficacy and safety of ZD6474 in patients with NSCLC after Failure of Prior Platinum-based Chemotherapy.
Checked against the public recordLast updated Aug 25, 2016 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 2
- Sponsor
- Genzyme, a Sanofi Company
- Interventions being studied
- Drug: ZD6474; Drug: Placebo; Drug: Docetaxel
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Histologic or cytologic confirmation of NSCLC (locally advanced or metastatic, IB-IV) * Failure of first-line platinum-based chemotherapy Exclusion Criteria: * Mixed small cell or non-small-cell histology * Bronchoalveolar carcinoma * Prior chemotherapy or herbal preparations must be discontinued more than 4 weeks before the start of study therapy (6 weeks for nitrosoureas, mitomycin and suramin) * Prior treatment with docetaxel
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Research SiteLos Angeles, California
- Research SiteJacksonville, Florida
- Research SiteAtlanta, Georgia
- Research SiteNew Orleans, Louisiana
- Research SiteBoston, Massachusetts
- Research SitePittsfield, Massachusetts
- Research SiteAnn Arbor, Michigan
- Research SiteDetroit, Michigan
- Research SiteBillings, Montana
- Research SiteGreat Neck, New York
- Research SiteNew York, New York
- Research SiteDurham, North Carolina
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Aug 25, 2016. Always confirm current availability with the study team.